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OBJECTIVE
Latent autoimmune diabetes in adults (LADA) shares clinical features with both
type 1 and type 2 diabetes; however, there is ongoing debate regarding the precise
deﬁnition of LADA. Understanding its genetic basis is one potential strategy to gain
insight into appropriate classiﬁcation of this diabetes subtype.
RESEARCH DESIGN AND METHODS
We performed the ﬁrst genome-wide association study of LADA in case subjects of
European ancestry versus population control subjects (n = 2,634 vs. 5,947) and
compared against both case subjects with type 1 diabetes (n = 2,454 vs. 968) and
type 2 diabetes (n = 2,779 vs. 10,396).
RESULTS
The leading genetic signals were principally shared with type 1 diabetes, although
we observed positive genetic correlations genome-wide with both type 1 and type
2 diabetes. Additionally, we observed a novel independent signal at the known
type 1 diabetes locus harboring PFKFB3, encoding a regulator of glycolysis and
insulin signaling in type 2 diabetes and inﬂammation and autophagy in autoim-
mune disease, as well as an attenuation of key type 1–associated HLA haplo-
type frequencies in LADA, suggesting that these are factors that distinguish
childhood-onset type 1 diabetes from adult autoimmune diabetes.
CONCLUSIONS
Our results support the need for further investigations of the genetic factors that
distinguish forms of autoimmune diabetes as well as more precise classiﬁcation
strategies.
The relationship between latent autoimmune diabetes in adults (LADA) and both
type 1 and type 2 diabetes is not fully elucidated and not appropriately encapsulated in
the term “type 1.5 diabetes” (1–3). In many populations, LADA is at least as prevalent
as childhood-onset type 1 diabetes (4) but is frequently misdiagnosed as type 2
diabetes (5,6) given its presentation in adults without need for insulin. As such,
subjects with LADA could be present in cohort studies for type 2 diabetes that do not
screen out autoantibody-positive case subjects, potentially resulting in the identi-
ﬁcation of genetic associations for type 2 diabetes that are etiologically related to
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autoimmunity. Furthermore, LADA has
a natural history distinct from that of
type 2 diabetes and is likely mismanaged
as a result (5). The challenge to deﬁne
adult autoimmune diabetes, including
LADA, as distinct from the generality of
type 2 diabetes is acute given the increas-
ingly larger data sets assembled to identify
additional, common genetic risk factors
of increasingly smaller effect sizes. Indeed,
reﬂecting this concern, recent genome-
wide association study (GWAS) analyses
of type 2 diabetes have reported associ-
ations at type 1 diabetes–associated re-
gions such as HLA-DQA1 in populations of
European ancestry (7) andHLA-B and INS-
IGF2 in populations of African ancestry
(8). As such, understanding the genetic
etiology of adult autoimmune diabetes
will not only aid the characterization of
this relatively common form of diabetes,
but will also facilitate our understanding
of both type 1 and type 2 diabetes.
To date, the relatively limited candi-
date gene studies carried out for LADA
have supported a role for both type 1
and type 2 diabetes risk loci (1,9–15).
Most notable from these previous studies
is the implicated role of the key type 2
diabetes–associated TCF7L2 locus in the
pathogenesis of LADA (11,13,16). More
recently, we constructed genetic risk scores
combining known type 1 and type 2 di-
abetes loci and assessed their impact in
LADA, and our results implicated a role for
both sets of loci (12). However, no system-
atic genome-wide appraisal of adult au-
toimmune diabetes has been performed.
Therefore, in this study, we performed
the ﬁrst GWAS of LADA against population
control subjects and further contrasted
LADA against type 1 and type 2 diabetes
to better understand its genomic signa-
ture in comparison with these two better
characterized forms of diabetes.
RESEARCH DESIGN AND METHODS
Study Subjects
Case subjects diagnosed with LADA were
included from cohorts of European an-
cestry (Supplementary Table 1), including
Action LADA (includes samples from the
U.K., Germany, and U.S.), All New Dia-
betics In Scania (ANDIS), the Botnia
Study, Copenhagen LADA (includes sam-
ples from the Danish Centre for Strategic
Research in Type 2 Diabetes, Vejle Diabetes
Biobank, Odense University Hospital, Co-
penhagen Insulin and Metformin Therapy
Trial, Inter99, Steno Diabetes Center),
the Diabetes Registry Vaasa (DIREVA),
Genetics of Diabetes Audit and Research
in Tayside Scotland (GoDARTS), Nord-
Trøndelag Health Study (HUNT), and Sca-
nia Diabetes Registry (SDR). Control
subjectswerepopulation-based (including
samples from the Bone Mineral Density in
Childhood Study [BMDCS], Copenhagen
control subjects [with samples from
the 1936 Birth Cohort and ADDITION-
PRO], GoDARTS, HUNT, the Malmo¨ Diet
and Cancer Study, DIREVA, and SDR).
Inclusion and exclusion criteria for
LADA, type 1 diabetes, type 2 diabetes,
and population control subjects varied by
cohort (see Supplementary Table 1 and
Supplementary Data for details). In gen-
eral, LADA was deﬁned by an age at diag-
nosis older than 20, 30, or 35 years, with
some cohorts restricting the upper age
limit to 70 years; the presence of diabetes-
associated autoimmune autoantibodies,
in particular GAD autoantibody (GADA)
positivity; and the lack of insulin require-
ment for 6 months or 1 year after diagno-
sis. In some case subjects, C-peptide level
was also used as a ﬁlter. This study was
approved by local institutional ethical re-
view boards for all participating centers.
Genotyping and Imputation
Each respective cohort performed genome-
wide genotyping on the IlluminaCoreExome
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chip, the Illumina OmniExpressExome
BeadChip, or the Affymetrix 6 array.
Case and control subjects from each
study center were matched on the
same genotyping chip to reduce batch
effects. Standard post-genotyping qual-
ity control was performed, including sam-
ple exclusions for ambiguous gender, call
rate ,95%, and any duplicate or related
individuals (pi_hat $0.2), and single nu-
cleotide polymorphism (SNP) exclusions
for monomorphic SNPs, SNPs with minor
allele frequency ,0.05, and SNPs with
missingness rate .0.05. The Haplotype
Reference Consortium imputation ser-
vice (Michigan imputation server, https://
imputationserver.sph.umich.edu/index
.html) was used to perform imputation
for autosomal SNPs.
Genome-Wide Association and
Meta-analysis: LADA Versus Control
Subjects, LADA Versus Type
1 Diabetes, and LADA Versus
Type 2 Diabetes
SNPTEST (17) or Efﬁcient and Parallelizable
Association Container Toolbox (http://
genome.sph.umich.edu/wiki/EPACTS)
was used by each respective cohort to
perform case-control GWAS of LADA (n =
2,634) versus population control subjects
(n = 5,947), LADA (n = 2,454) versus case
subjects with type 1 diabetes (n = 968),
and LADA (n = 2,779) versus case subjects
with type 2 diabetes (n = 10,396), in-
cluding sex and principal components as
covariates (see Supplementary Table 1
for cohort-speciﬁc covariates).
After GWAS, ﬁltering was performed
centrally to include only SNPs with a
minor allele frequency.0.05, INFOqual-
ity score .0.4, and a Hardy-Weinberg
equilibrium P. 13 1027. Meta-analysis
was then performed for LADA versus
population control subjects, LADA versus
type 1 diabetes, and LADA versus type 2
diabetes with GWAMA (18) with two
rounds of genomic control (Supplemen-
tary Table 2 and Supplementary Figs. 1
and 2).
Signals in the secondary tier (P = 1 3
1026 to 5 3 1028) for the LADA versus
population control subject analysis were
followed up in the GoDARTS and HUNT
cohorts (LADA, n = 345; control subjects,
n = 1,664) and meta-analyzed with the
discovery set (total LADA, n = 2,979;
control subjects, n = 7,611) to assess
whether any novel signals would reach
genome-wide signiﬁcance.
Enrichment of Directional
Consistency Among Type 1 Diabetes/
Type 2 Diabetes Loci in LADA
To estimate whether the concordance in
direction of effects for type 1 and type 2
diabetes loci in LADA is signiﬁcantly dif-
ferent from chance, a binomial test was
used, assuming a null hypothesis of 50%
agreement.
Conditional Analysis
Approximate conditional analysis for
known type 1 diabetes–associated loci
was carried out for the LADA versus con-
trol subject summary statistics results for
the 10p15.1 locus using genome-wide
complex trait analysis (19). For this locus,
LADA versus control subjects plus HUNT
summary statistics were conditioned on
the following type 1 diabetes–associated
SNPs: rs61839660 (20), rs10795791 (20),
rs7090530 (21), rs12251307 (22),
rs41295121 (20), and rs11258747 (22).
We did not condition on the signiﬁcant
signals at other loci. For 12q24.3, two
of the type 1 diabetes–associated SNPs
(rs3184504 [22] and rs653178 [20])
were in high linkage disequilibrium (LD;
r2. 0.9) with our lead SNP. Additionally,
the MHC, PTPN22, and INS loci were not
conditioned, as the top signals were iden-
tiﬁed as type 1 diabetes–associated SNPs.
Stratiﬁcation Analysis by GADA Titer
Case subjects with LADA are heteroge-
neous in terms of GADA titer (23). There-
fore, to further understand the genetic
landscape of LADA in the context of
different GADA levels, we stratiﬁed
case subjects into tertiles in Action
LADA, ANDIS, DIREVA, and SDR. We
performed three GWAS on 1) the top
tertile with the highest GADA titers (n =
627) versus population control subjects
(n = 4,314), 2) the top two tertiles with
the highest GADA titers (n = 1,012) versus
population control subjects (n = 4,314),
and 3) the bottom tertile with the low-
est GADA titers (n = 562) versus popula-
tion control subjects (n = 4,314).
LD Score Regression
To test for genetic correlations genome-
wide among LADA, type 1 diabetes (21),
and type 2 diabetes (24), we used LD
score regression through the LDSC
v.1.0.0 python package (25).
Pathway Analysis
DEPICT pathway analysis (26) was used to
perform gene set enrichment, tissue en-
richment, and geneprioritization analyses.
HLA Imputation/Analysis
The HLA imputation software SNP2HLA
(27) was used to impute chromosome
6 in Action LADA (n = 1,365), Swedish
case subjects with LADA (n = 794), BMDCS
(n = 1,056), and case subjects with
type 1 diabetes from the Wellcome Trust
Case Control Consortium (n = 1,990).
HLA alleles with four-digit resolution
were imputed. The R package BIGDAWG
(https://cran.r-project.org/web/packages/
BIGDAWG) (28) was used to test for allele
frequency differences for established
type 1 diabetes–associated HLA haplo-
types between LADA versus type 1 di-
abetes as well as LADA versus BMDCS.
Haplotypes with frequencies,1% across
LADA, type 1 diabetes, and BMDCS were
removed from the analysis given that
rare haplotypes can result in unstable
variance estimates and unreliable test
statistics.
RESULTS
Genome-Wide Association of LADA
Versus Population Control Subjects
We ﬁrst conducted GWAS in patients with
LADA (n = 2,634) versus population-based
control subjects (n = 5,947) of European
ancestry in a discovery meta-analysis set-
ting (Supplementary Table 1) (power cal-
culations can be found in Supplementary
Table 3). Four signals achieved genome-
wide signiﬁcance (P , 5 3 1028), all at
established type 1 diabetes risk loci (HLA,
PTPN22, INS, and SH2B3) (Table 1 and
Supplementary Figs. 1 and 2). Pathway
analysis with DEPICT (26) for signals at P,
1025 supported a strong immune role
in the pathogenesis of LADA (Supple-
mentary Tables 4 and 5), with gene set
enrichment analysis implicating abnor-
mal cytotoxic T-cell physiology (nominal
P = 6.39 3 1027) as well as the mTOR
subnetwork (P =6.0331025) and cell cycle
(P = 1.67 3 1025), as also seen in a pre-
vious epigenome-wide association study
of type 1 diabetes (7), and immune sys-
tem tissue types, including natural killer
cells and T lymphocytes (nominal P =
0.0079 and 0.0082, respectively). This is
consistent with previous reports of these
cell types playing a role in the pathogen-
esis of type 1 diabetes and LADA (29,30).
Replication Supports a Novel Locus
at 6-Phosphofructo-2-Kinase/
Fructose-2,6-Biphosphatase 3
Using case subjects with LADA and pop-
ulation samples from an additional two
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study centers, we attempted validation
of 13 signals with suggestive association
(P, 53 1025) (Supplementary Table 6).
We observed a novel signal at 10p15.1
between the two established type 1 di-
abetes loci at IL2RA and PRKCQ, which
achieved genome-wide signiﬁcance
(rs1983890-C, odds ratio [OR] [95%
CI] = 1.16 [1.14–1.32]; P = 3.02 3 1028)
(Fig. 1A and B). Given that the LADA
signal is situated in close proximity to
known type 1 diabetes risk loci and was
in moderate-to-low LD with established
type 1 diabetes–associated alleles (Sup-
plementary Table 7), we conditioned on
the type 1 diabetes SNPs and observed
that rs1983890 remained strongly asso-
ciated with LADA (OR [95% CI] = 1.15
[1.13–1.19]; P = 4.35 3 1028) (Fig. 1C).
This signal reached suggestive associa-
tion in a study of type 1 diabetes (P =
1.3 3 1027) (21) and as such may not
represent a unique LADA association.
DEPICT gene prioritization analysis
(26) identiﬁed the gene encoding 6-
phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 (PFKFB3), the nearest
gene to the LADA signal, as the most
likely functional candidate (Supplemen-
tary Table 8).
Candidate Loci for Type 1 Diabetes
and Type 2 Diabetes
Some of the loci that were suggestively
associated with LADA in this study over-
lap previously documented type 1 diabetes
associations, including rs11755527 (BACH2)
and rs941576 (DLK1) (20–22), and the
type 2 diabetes association at rs11888640
(THADA). Taking a candidate gene ap-
proach, we extracted 66 established
type 1 diabetes–associated loci from
the LADA versus population control sub-
ject meta-analysis and found that 17 of
these yielded association with LADA
after multiple-test correction (P , 7.6 3
1024) (Supplementary Table 9). Taking
a similar approach with 65 established
type 2 diabetes loci, none surpassed the
signiﬁcance threshold; however, at the
nominal signiﬁcance level (P , 0.05),
11 type 1 diabetes and 11 type 2 diabetes
variants were associated with LADA, all
having the same direction of effect as
seen for type 1 diabetes and type 2
diabetes, respectively, except for the
type 2 diabetes locus CILP2 (rs10401969-
T, OR [95% CI] = 0.820 [0.726–0.927]; P =
0.0016) (Supplementary Table 10). On
the whole, both type 1 and type 2 di-
abetes loci had lower P values in LADA
than expected by chance (Supplementary
Fig. 3). Approximately 90.6% of type 1
diabetes loci (Supplementary Table 9)
had directional consistency in LADA (P =
4.513 10212) and 72.3% of type 2 diabetes
loci (Supplementary Table 10) had di-
rectional consistency in LADA (P = 2.103
1024). Combining type 1 and type 2 di-
abetes loci, 81.4% had directional con-
sistency in LADA (P = 1.40 3 10213).
Therefore, we observed a signiﬁcant
enrichment of established type 1 and
type 2 diabetes loci having the same
directional effect in LADA.
GWAS of LADA Versus Type 2 and
Type 1 Diabetes
Next, we compared LADA with type 2
diabetes at the genome-wide level. Sim-
ilar to the results of LADA versus pop-
ulation control subjects, LADA (n = 2,454)
versus type 2 diabetes (n = 10,396)
yielded genome-wide signiﬁcance for
the same four type 1 diabetes risk loci
(Table 1). We then performed a GWAS of
LADA (n = 2,454) versus type 1 diabetes
(n = 968) to assess whether any differ-
ences could be detected. Only the HLA
region was signiﬁcantly different be-
tween type 1 diabetes and LADA, repre-
senting a relative depletion of the lead
signal in LADAwhen compared with type
1 diabetes (rs9273368-A, OR [95% CI] =
0.335 [0.256–0.385]; P = 8.46 3 10240)
(Table 1). Leveraging the entire genome-
wide summary statistics, genetic corre-
lation analyses showed that LADA was
positively correlated with both type 1
diabetes (with the inclusion of the HLA;
rg [SE] = 0.385 [0.136]; P = 0.0047) and
type2diabetes (without theHLA; rg [SE] =
0.281 [0.106]; P = 0.008).
Stratiﬁed GWAS of LADA by GADA
Tertile
Stratifying LADA case subjects into ter-
tiles resulted in the detection of the same
four loci, although the magnitude of the
Table 1—Genome-wide signiﬁcant signals associated with LADA
SNP Chromosome
Position
(b37)
Reference/
otherallele
Effect allele frequency
(case/control subjects) OR 95% CI P Gene
LADA (n = 2,634) vs.
population control
subjects (n = 5,947)
rs9273368 6 32626475 A/G 0.50/0.28 3.115 2.855–3.398 7.873102143 HLA-DQB1
rs2476601 1 114377568 A/G 0.159/0.102 1.717 1.539–1.915 7.21 3 10222 PTPN22
rs689 11 2182224 T/A 0.802/0.726 1.483 1.363–1.613 1.07 3 10219 INS
rs7310615 12 111865049 C/G 0.553/0.492 1.284 1.193–1.383 4.92 3 10211 SH2B3
LADA (n = 2,779) vs. case
subjects with type 2
diabetes (n = 10,396)
rs9273368 6 32626475 A/G 0.43/0.301 2.439 2.222–2.676 3.17 3 10278 HLA-DQB1
rs689 11 2182224 T/A 0.783/0.715 1.473 1.352–1.605 9.86 3 10219 INS
rs2476601 1 114377568 A/G 0.173/0.140 1.529 1.38–1.693 4.52 3 10216 PTPN22
rs3184504 12 111884608 C/T 0.544/0.52 1.24 1.151–1.336 1.77 3 1028 SH2B3
LADA (n = 2,454) vs. case
subjects with type 1
diabetes (n = 968)
rs9273368 6 32626475 A/G 0.415/0.65 0.335 0.256–0.385 8.46 3 10240 HLA-DQB1
We performed three genome-wide association approaches, ﬁrst for LADA vs. population control subjects (top), then for LADA vs. type 2 diabetes
(middle), and ﬁnally for LADA versus type 1 diabetes (bottom). ORs are given for the LADA risk allele, except for rs9273368 in LADA vs. type 1 diabetes,
to illustrate that the type 1 diabetes risk allele was depleted in LADA.
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associations differed between the top
tertile versus population control sub-
jects, the top two tertiles versus popu-
lation control subjects, and the bottom
tertile versus population control subjects
(Supplementary Table 11). As expected,
the ORs for the leading loci were stron-
gest in the case subjects with LADA with
the highest GADA titers. For example,
rs9273368 (HLA-DQB1) showed the
strongest association with LADA in the
analysis including the top tertile of GADA
titer (OR [95% CI) = 3.30 [2.81–3.88]; P =
1.89 3 10247) and the lowest association
in the bottom GADA tertile (OR [95% CI] =
2.42 [2.06–2.85]; P = 2.13 3 10226).
Furthermore, only the HLA-DQB1 locus
was signiﬁcantly associated in the case
subjects with LADA with the lowest GADA
titers, whereas the PTPN22, INS, and
SH2B3 loci were only evident among
case subjects with higher GADA titers.
Furthermore, rs7903146 at TCF7L2
had a slightly higher OR in the group
with the lowest GADA titer than that with
the highest GADA titer (1.09 vs. 1.05,
respectively).
HLA Haplotype Analysis
To further investigate differences in the
HLA region between LADA and type 1
diabetes, we imputed this region using
SNP2HLA (27) in 2,159 case subjects with
LADA from the Action LADA plus Chil-
dren’s Hospital of Philadelphia plus Swed-
ish cohorts and 1,990 patients with type
1 diabetes (Wellcome Trust Case Con-
trol Consortium [31]) and compared
the frequencies of the leading type 1
diabetes–associated HLA haplotypes
(Supplementary Table 12). After remov-
ing haplotypes with ,1% frequency,
15 known type 1 diabetes–associated
HLA haplotypes were tested for associ-
ation in LADA compared with type 1
diabetes. Eleven type 1 diabetes haplo-
types were signiﬁcantly different in fre-
quency between case subjects with
LADA and type 1 diabetes after correc-
tion formultiple testing (P, 0.003), with
all but four being protective against
type 1 diabetes (32). The four type 1
diabetes susceptibility haplotypes, HLA-
DRB1*0301-DQA1*0501-DQB1*0201,
HLA-DRB1*0401-DQA1*0301-DQB1*0302,
HLA-DRB1*0404-DQA1*0301-DQB1*0302,
and HLA-DRB1*0405-DQA1*0301-DQB1*
0302 (32), had signiﬁcantly lower frequen-
cies in LADA than in type 1 diabetes.
Figure 1—LocusZoom plots for the PFKFB3 locus. A: In LADA vs. population control subjects with
the addition of replication samples, rs1983890 reached borderline genome-wide signiﬁcance.
B: This signal lies in between two type 1 diabetes–associated loci at 10p15.1 (21). C: When
we conditioned on the two known type 1 diabetes loci, the signal in LADA remained. LocusZoom
plots were constructed to show the association data of SNPs 400 kb upstream and downstream
of the lead LADA-associated signal at rs1983890. chr10, chromosome 10.
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CONCLUSIONS
Taken collectively, GWAS and HLA hap-
lotype analyses based on established
associations, along with gene set enrich-
ment analyses, support the hypothesis
that the strongest genetic risk loci for
LADA are shared with type 1 diabetes but
that established type 2 diabetes alleles
also play a weaker role, as evidenced
by the enrichment of established type
2 diabetes loci in LADA and the posi-
tive genetic correlation between LADA
and type 2 diabetes. The strong type 1
diabetes–like signature seen in this study
in adult autoimmune diabetes could be
explained by the differing genetic archi-
tectures between the two main types of
diabetes (33), with type 1 diabetes hav-
ing multiple low-frequency risk variants
with high ORs, whereas type 2 diabetes
has many common risk variants with
smaller effect sizes. Given these architec-
tural differences, any trait with a type 1
diabetes–like genetic component will
detect type 1 signals ﬁrst and would
only subsequently detect the type 2 sig-
nals with increased statistical power (Sup-
plementary Table 3).
Furthermore, this has important im-
plications for genetic studies of type 2
diabetes, in which case subjects with
misdiagnosed autoimmune diabetes are
not routinely screened out. With increas-
ing sample sizes and the ability to detect
additional loci, type 2 diabetes GWAS
that are contaminated with adult auto-
immune case subjects will inevitably begin
to detect type 1 diabetes–associated ge-
netic loci, potentially misassigning these
loci to type 2 diabetes etiology.
In comparing LADA to the general
population, we identiﬁed a novel inde-
pendent genome-wide signiﬁcant signal
at the PFKFB3 locus that persisted after
conditioning on the two nearby type 1
diabetes–associated signals on chromo-
some 10p15. Cumulative evidence for
the 10p15 locus suggests it is a complex
region associated with autoimmune di-
abetes, given that it already harbors two
established risk alleles for type 1 diabetes
(21,22) as well as our signal for LADA.
Previous studies strongly support PFKFB3
as a plausible biological candidate in
diabetes, given its gene product’s role
as a regulator of glycolysis and insulin
signaling (34). In mice, a pair of comple-
mentary studies showed that disrupted
PFKFB3 in adipose tissue exacerbated
insulin resistance and adipose tissue in-
ﬂammation (35), whereas overexpres-
sion of the gene was protective (36).
Furthermore, PFKFB3 plays a role in auto-
immune diseases; in T cells from patients
with rheumatoid arthritis, PFKFB3 is
lost, leading to decreased T-cell glucose
consumption and impaired autophagy,
which in turn lead to an inability to
mount a normal immune response and
an increase in T-cell apoptosis (37). Fur-
ther studies are thus warranted to in-
vestigate the role of PFKFB3 in LADA
and to determine whether this signal is
truly a distinguishing feature between
adult and childhood-onset autoimmune
diabetes.
Although the lead genome-wide sig-
niﬁcant loci are shared with those for
type 1 diabetes risk, they clearly have a
diminished impact in LADA. To further
investigate the differences between
LADA and type 1 diabetes at the HLA
region, we performed a comparative
haplotype analysis that showed a de-
creased frequency of type 1 diabetes-
associated risk haplotypes in LADA. This
could be partly explained by the estab-
lished age gradient in HLA frequencies
seen in patients with type 1 diabetes (38);
however, HLA risk genotype frequen-
cies have also been shown to differ
between patients with LADA and pa-
tients with type 1 diabetes with age at
onset older than 35 years (14,39). Fu-
ture in-depth studies of the differences
in HLA risk haplotypes between type 1
diabetes and LADA, taking age and eth-
nicity into account, are therefore also
warranted.
In terms of type 2 diabetes–associated
loci, our results differ from previous
candidate studies. For instance, our pre-
viously reported HNF1A (12) locus was
not observed in this setting. Further-
more, although previous studies showed
an association for the leading type 2
diabetes risk locus at TCF7L2 with
LADA (11,16), our data show relatively
limited support of this ﬁnding (Sup-
plementary Table 10) (LADA vs. popu-
lation control subjects, rs7903146-T: OR
[95% CI] = 1.107 [1.024–1.20]; P = 0.011),
which may be due to the limited power
of our study to detect type 2 diabetes
signals (Supplementary Table 2). To un-
derstand the evidence supporting the
previous association, we examined the
allele frequencies of the lead variant in
each contributing cohort. This revealed
that the difference in risk allele frequency
between case and control subjects was
cohort speciﬁc, with only one case-control
set (Action LADA case vs. BMDCS con-
trol subjects) not supporting this asso-
ciation, principally due to the higher
frequency of the risk allele in the control
set (Supplementary Table 13). One pos-
sibility is that inclusion or exclusion of
patients with type 2 diabetes from con-
trol cohorts would affect the frequency
of the risk allele; however, sensitivity
analysis with control sets that either
excluded or included patients with di-
abetes in Swedish and Danish samples
showed the persistence of an association
(Supplementary Table 13), although not
at the genome-wide signiﬁcance level.
Interestingly, a recent study found that
the type 2 diabetes risk allele at the key
TCF7L2 locus was associated with case
subjects with type 1 diabetes who were
older than 12 years at onset and positive
for only a single autoimmune antibody
(40). That study provides further evidence
for a role for type 2 diabetes genetic risk in
later-onset autoimmune diabetes and
resonates with the genome-wide obser-
vations we report in this study in adults.
The precise diagnostic criteria used to
distinguish LADA from adult-onset type 1
and type 2 diabetes remain under debate.
These differences in opinion have hin-
dered the collection of well-phenotyped,
clearly deﬁned LADA cohorts for
genetic studies and are reﬂected in
the cohorts we included in this study
(e.g., in terms of heterogeneous age
inclusion thresholds and differences in
autoantibody testing). In this study, we
strove to be inclusive to maximize our
sample size and statistical power, but we
acknowledge that stringent, deeply phe-
notyped cohorts are needed to truly
address where adult autoimmune diabe-
tes is placed on the diabetes spectrum.
Another debate surrounds the idea that
LADA cohorts may simply be collections
of poorly phenotyped case subjects with
adult-onset type 1 and type 2 diabetes
and refutes the idea that LADA is a uni-
que disease entity. However, GADA assays
have a speciﬁcity of 95–98%, so by im-
plication, some case subjects with type 2
diabetes with low-level GADA can be
incorrectly classiﬁed as case subjects
with LADA; these would, however, rep-
resent only a very small fraction of case
subjects because the predictive speciﬁcity of
GADA would have been increased by our
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cohort enrichment as with any biomarker
assay. Conversely, the small percentage
of case subjects with LADA who do not
have GADA positivity but have other islet
autoantibodies and are misclassiﬁed as
having type 2 diabetes could affect the
estimate of genetic correlation between
LADA and type 2 diabetes to a small
degree. Future studies should focus on
deﬁning the heterogeneity and misdiag-
nosis rates among patients with LADA.
Despite these limitations, using the
deﬁnition of LADA presented in this
study, we identiﬁed factors that poten-
tially distinguish this form of adult
autoimmune diabetes from childhood-
onset type 1 diabetes as well as type 2
diabetes: 1) a novel signal at the PFKFB3
locus and 2) attenuation of type 1–
associated HLA risk haplotypes. Overall,
we ﬁnd the presence of both a type 1
diabetes–like autoimmune genetic compo-
nent and a type 2 diabetes–like metabolic
genetic component consistent with the
phenotypic features of both main dia-
betes types, suggesting that LADA as de-
ﬁned in this study is a hybrid of these
two major diseases. Our ﬁndings pro-
mote the hypothesis that the polygenic
component that contributes susceptibil-
ity to type 2 diabetes can act as a mod-
iﬁer to type 1 diabetes risk, possibly as
a “second hit” in individuals who have
moderate underlying autoimmune sus-
ceptibility that is insufﬁcient to trigger
childhood type 1 diabetes but greater
than that of the general population and
sufﬁcient to lead to clinical diabetes in
adulthood. Taken together, future studies
should examine the role of BMI, which is
lower in type 1 diabetes and higher among
patients with type 2 diabetes, in adult
autoimmune diabetes, as well as further
deﬁning the role of factors that poten-
tially distinguish adult autoimmune di-
abetes from type 1 and type 2 diabetes.
Conclusion
In this ﬁrst GWAS of LADA, we show that
the leading genome-wide signiﬁcant sig-
nals point toward LADA as being a late-
onset form of type 1 diabetes, albeit with
a genetically attenuated potency of key
type 1 diabetes–associated HLA haplo-
types, but also with a type 2 diabetes–
like genetic component. Further in-depth
studies are necessary to address how
LADA and insulin dependence develop
and to study the impact of heterogene-
ity among case subjects with LADA, as
well as a need for functional studies to
investigate how the glycolytic regulator
PFKFB3 is situated at the intersection of
autoimmune and metabolic diabetes.
Furthermore, our LADA data set should
act as a resource to help mitigate the
unaccounted presence of autoimmune
diabetes in patients masquerading as
type 2 diabetes, with implications for
both GWAS and clinical management.
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